China
· Delayed Price · Currency is CNY Sansure Biotech Statistics
Total Valuation
Sansure Biotech has a market cap or net worth of CNY 11.57 billion. The enterprise value is 8.00 billion.
| Market Cap | 11.57B |
| Enterprise Value | 8.00B |
Important Dates
The next estimated earnings date is Tuesday, August 19, 2025.
| Earnings Date | Aug 19, 2025 |
| Ex-Dividend Date | Jun 11, 2025 |
Share Statistics
Sansure Biotech has 574.18 million shares outstanding. The number of shares has increased by 0.64% in one year.
| Current Share Class | 574.18M |
| Shares Outstanding | 574.18M |
| Shares Change (YoY) | +0.64% |
| Shares Change (QoQ) | -7.69% |
| Owned by Insiders (%) | 42.11% |
| Owned by Institutions (%) | 12.27% |
| Float | 280.39M |
Valuation Ratios
The trailing PE ratio is 41.17 and the forward PE ratio is 30.53.
| PE Ratio | 41.17 |
| Forward PE | 30.53 |
| PS Ratio | 7.50 |
| PB Ratio | 1.56 |
| P/TBV Ratio | 1.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 31.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.60, with an EV/FCF ratio of -111.02.
| EV / Earnings | 27.95 |
| EV / Sales | 5.19 |
| EV / EBITDA | 27.60 |
| EV / EBIT | 61.39 |
| EV / FCF | -111.02 |
Financial Position
The company has a current ratio of 4.44, with a Debt / Equity ratio of 0.11.
| Current Ratio | 4.44 |
| Quick Ratio | 4.07 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 2.91 |
| Debt / FCF | -11.72 |
| Interest Coverage | 6.82 |
Financial Efficiency
Return on equity (ROE) is 3.12% and return on invested capital (ROIC) is 1.00%.
| Return on Equity (ROE) | 3.12% |
| Return on Assets (ROA) | 0.88% |
| Return on Invested Capital (ROIC) | 1.00% |
| Return on Capital Employed (ROCE) | 1.56% |
| Revenue Per Employee | 657,546 |
| Profits Per Employee | 122,040 |
| Employee Count | 2,346 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.84 |
Taxes
In the past 12 months, Sansure Biotech has paid 33.93 million in taxes.
| Income Tax | 33.93M |
| Effective Tax Rate | 12.69% |
Stock Price Statistics
The stock price has increased by +8.38% in the last 52 weeks. The beta is 0.67, so Sansure Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | +8.38% |
| 50-Day Moving Average | 19.92 |
| 200-Day Moving Average | 21.08 |
| Relative Strength Index (RSI) | 51.38 |
| Average Volume (20 Days) | 4,061,579 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sansure Biotech had revenue of CNY 1.54 billion and earned 286.31 million in profits. Earnings per share was 0.49.
| Revenue | 1.54B |
| Gross Profit | 1.23B |
| Operating Income | 130.37M |
| Pretax Income | 267.43M |
| Net Income | 286.31M |
| EBITDA | 280.94M |
| EBIT | 130.37M |
| Earnings Per Share (EPS) | 0.49 |
Balance Sheet
The company has 4.50 billion in cash and 844.66 million in debt, giving a net cash position of 3.66 billion or 6.37 per share.
| Cash & Cash Equivalents | 4.50B |
| Total Debt | 844.66M |
| Net Cash | 3.66B |
| Net Cash Per Share | 6.37 |
| Equity (Book Value) | 7.43B |
| Book Value Per Share | 12.79 |
| Working Capital | 4.47B |
Cash Flow
In the last 12 months, operating cash flow was 366.28 million and capital expenditures -438.37 million, giving a free cash flow of -72.09 million.
| Operating Cash Flow | 366.28M |
| Capital Expenditures | -438.37M |
| Free Cash Flow | -72.09M |
| FCF Per Share | -0.13 |
Margins
Gross margin is 79.48%, with operating and profit margins of 8.45% and 18.56%.
| Gross Margin | 79.48% |
| Operating Margin | 8.45% |
| Pretax Margin | 17.34% |
| Profit Margin | 18.56% |
| EBITDA Margin | 18.21% |
| EBIT Margin | 8.45% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.53, which amounts to a dividend yield of 2.61%.
| Dividend Per Share | 0.53 |
| Dividend Yield | 2.61% |
| Dividend Growth (YoY) | 13.59% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 95.95% |
| Buyback Yield | -0.64% |
| Shareholder Yield | 1.97% |
| Earnings Yield | 2.47% |
| FCF Yield | -0.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.48.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.48 |
Scores
Sansure Biotech has an Altman Z-Score of 4.64 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.64 |
| Piotroski F-Score | 6 |